Linolenic Acid Attenuates the Vasodilation Induced by Acetylcholine in Isolated Rat Aortae

Soo Hee Lee¹, Seong-Ho Ok², Ji-Yoon Kim¹, Raghavendra Baregundi Subbarao¹, Sung Il Bae¹, Yeran Hwang¹, Kyeong-Eon Park¹, Jong Won Kim¹, and Ju-Tae Sohn³,⁴

Abstract
This study aims to examine the effect of linolenic acid on the vasodilation or vasoconstriction induced by acetylcholine and bupivacaine in isolated rat aortae and its underlying mechanism. The effect of linolenic acid on the vasodilation induced by acetylcholine, the calcium ionophore A23187, sodium nitroprusside, and 8-bromoguanosine 3',5'-cyclic monophosphate sodium salt (bromo-cyclic guanosine monophosphate [bromo-cGMP]) in endothelium-intact and endothelium-denuded aortae was examined. Linolenic acid inhibited vasodilation induced by acetylcholine, calcium ionophore A23187, and sodium nitroprusside. However, this fatty acid increased bromo-cGMP-induced vasodilation in endothelium-denuded aortae. Linolenic acid increased bupivacaine-induced contraction in endothelium-intact aortae, whereas it decreased bupivacaine-induced contraction in endothelium-intact aortae with N°-nitro-L-arginine methyl ester and endothelium-denuded aortae. Linolenic acid inhibited acetylcholine- and bupivacaine-induced phosphorylation of endothelial nitric oxide synthase. Sodium nitroprusside increased cGMP in endothelium-denuded aortic strips, whereas bupivacaine decreased cGMP in endothelium-intact aortic strips. Linolenic acid decreased cGMP levels produced by bupivacaine and sodium nitroprusside. Together, these results suggest that linolenic acid inhibits acetylcholine-induced relaxation by inhibiting a step just prior to nitric oxide-induced cGMP formation. In addition, linolenic acid-mediated inhibition of vasodilation induced by a toxic concentration (3 × 10^-4 M) of bupivacaine seems to be partially associated with inhibition of the nitric oxide–cGMP pathway.

Keywords
linolenic acid, acetylcholine, bupivacaine, nitric oxide, endothelial nitric oxide synthase, cyclic guanosine monophosphate

Introduction
Lipid emulsion is effective in treating local anesthetic systemic toxicity.¹ In addition, lipid emulsion as a nonspecific antidote has been reported to be effective in alleviating cardiovascular collapse induced by toxic doses of highly lipid soluble drugs (log [octanol/water partition coefficient]: >2.0), including verapamil, amlodipine, and diphenhydramine.¹,² Intralipid, whose fatty acid component consists of 100% long-chain fatty acids, attenuates acetylcholine-induced nitric oxide (NO)-mediated relaxation.³ Furthermore, Intralipid increases left ventricular systolic pressure via the inhibition of NO.³ In addition, administration of lipid emulsions causes increased blood pressure and systemic vascular resistance.⁵⁻⁸ Intralipid, which is derived from soybean oil, contains 53% linoleic acid, 24% oleic acid, 11% palmitic acid, 8% linolenic acid, and 4% stearic acid.⁹ Both linoleic acid (C18:2n-6) and linolenic acid (C18:3n-3)
among long-chain fatty acids contained in Intralipid are essential fatty acids, which should be supplied by diet, and polyunsaturated long-chain fatty acids. Free fatty acids, including stearic acid, decrease acetylcholine-induced NO-mediated relaxation. Moreover, a toxic concentration of aminoamide local anesthetics induces vasodilation (attenuated vasoconstriction) partially mediated by endothelial NO release, whereas a lipid emulsion containing linolenic and linoleic acids inhibits vasodilation induced by a toxic concentration of levobupivacaine, which seems to be partially associated with the inhibition of endothelial NO release. On the other hand, ω-linolenic acid improves the impaired acetylcholine-induced relaxation caused by cigarette smoking, suggesting that ω-linolenic acid and its metabolite may induce NO production. First, the goal of this study is to examine the effect of long-chain polyunsaturated essential fatty acids, linolenic, and linoleic acid on acetylcholine-induced NO-mediated relaxation and to elucidate the underlying cellular mechanism. Second, the effects of linoleic acid on the concentration–response (vasoconstriction and vasodilation) curves induced by bupivacaine in isolated rat aortae and its underlying mechanism with a particular focus on endothelial NO were examined.

Materials and Methods

The Institutional Animal Care and Use Committee of Gyeongsang National University approved all the experimental protocols (GNU-160414-R0019), and all the experimental procedures were performed in accordance with the Guideline of the Care and Use of Laboratory Animal of Gyeongsang National University.

Preparation of Isolated Rat Aortae for Isometric Tension Measurement

Isolated rat aortae for isometric tension measurement were prepared as described previously. Carbon dioxide (100%) was used to euthanize male Sprague-Dawley (body weight: 250-300 g). The descending thoracic part of the aorta was dissected and removed from the thorax. Aortae were immersed in Krebs solution, which is composed of the following components (mM): sodium chloride (118), glucose (11), sodium bicarbonate (25), potassium chloride (4.7), calcium chloride (2.4), magnesium sulfate (1.2), and monopotassium phosphate (1.2). The periaortic tissues, such as fat and connective tissue, were removed under a microscope. The isolated aorta was cut into aortic rings 2.5 mm in length. The endothelium of some isolated descending thoracic aortae was removed by inserting two 25-gauge needles into the lumen of aortic rings and rolling the isolated aortic ring forward and backward. Isolated thoracic aortae were suspended in a Grass isometric transducer (FT-03, Grass Instrument, Quincy, Massachusetts) attached to an organ bath with 10 cc Krebs solution maintained at 37 C. Based on a previous similar experiment, a baseline resting tension of 3.0 g was chosen, and this baseline resting tension was maintained for 120 minutes to reach equilibrium. The Krebs solution was replaced by fresh Krebs solution every 40 minutes. The pH at 7.4 of Krebs solution was maintained by aerating Krebs solution with 95% oxygen and 5% carbon dioxide. To confirm endothelial integrity, after phenylephrine (10^{-7} M) produced a sustained and stable contraction, acetylcholine (10^{-5} M) was added into the organ bath, and more than 85% relaxation from phenylephrine-induced contraction was considered to be endothelium-intact aortic rings. In addition, to verify endothelial denudation of isolated rat aortae, after phenylephrine (10^{-8} M) produced a sustained and stable contraction, acetylcholine (10^{-5} M) was added into the organ bath, and less than 15% acetylcholine-induced relaxation was regarded as endothelium-denuded aortic rings. The isolated endothelium-intact and endothelium-denuded aortic rings showing acetylcholine-induced relaxation were washed with fresh Krebs solution to restore baseline resting tension. Then, the contraction was induced by isotonic 60 mM KCl in some isolated aortic rings, and this contraction was used as a reference value to express the magnitude of contraction induced by dexamethasone and bupivacaine. Krebs solution with isotonic 60 mM KCl used to induce contraction was composed of sodium chloride (63.2 mM), potassium chloride (60 mM), sodium bicarbonate (25 mM), glucose (10 mM), calcium chloride (2.4 mM), magnesium sulfate (1.2 mM), and monopotassium phosphate (1.2 mM). Then, the isolated aortic rings with isotonic 60 mM KCl-induced contraction were washed with fresh Krebs solution to restore baseline resting tension. The following experimental protocols were performed.

Experimental Protocol

First, the effect of linolenic and linoleic acid (5 \times 10^{-6} and 5 \times 10^{-5} M) on the NO-induced vasodilation produced by endothelial muscarinic receptor-mediated vasodilator acetylcholine in endothelium-intact rat aortae was examined. Isolated endothelium-intact rat aortae were pretreated with linolenic and linoleic acid for 20 minutes. Then, phenylephrine (10^{-6} M) was added into the organ bath to produce vasoconstriction in the presence or absence of either linolenic or linoleic acid and then acetylcholine (10^{-8} to 10^{-5} M) was cumulatively added into the organ bath to produce vasodilation induced by acetylcholine.

Second, the effect of linolenic acid (5 \times 10^{-5} M) on the vasodilation induced by endothelial receptor-independent vasodilator calcium ionophore A23187 and NO donor sodium nitroprusside in endothelium-intact and endothelium-denuded rat aortae was examined. Isolated endothelium-intact and endothelium-denuded rat aortae were examined. Isolated endothelium-intact and endothelium-denuded rat aortae were pretreated with linolenic acid for 20 minutes. Then, 10^{-6} and 10^{-7} M phenylephrine was added to the organ bath to produce a sustained and stable vasoconstriction in endothelium-intact and endothelium-denuded rat aortae, respectively, in the presence or absence of linolenic acid. Then, calcium ionophore A23187 (10^{-9} to 10^{-6} M) and sodium nitroprusside (10^{-10} to 10^{-7} M) were cumulatively added into the organ bath with endothelium-intact and endothelium-denuded rat aortae, respectively, to produce...
vasodilation induced by calcium ionophore A23187 or sodium nitroprusside.

Third, the effect of GW1100, an inhibitor of G-protein-coupled receptor 40, which is known as free fatty acid receptor 1, and ethanol, which is used for the dissolution of linolenic acid, on acetylcholine-induced NO-mediated relaxation in endothelium-intact rat aortae with or without linolenic acid was examined. The endothelium-intact rat aortae were pretreated with GW1100 (10^{-5} M) for 15 minutes followed by linolenic acid (5 \times 10^{-5} M) for 20 minutes or ethanol (0.1%) and linolenic acid (5 \times 10^{-5} M) alone for 20 minutes. Then, phenylephrine (10^{-6} M) was added into the organ bath to produce a sustained and stable contraction in the presence or absence of the combined treatment with GW1100 and linolenic acid, ethanol, or linolenic acid alone. Then, acetylcholine (10^{-8} to 10^{-5} M) was cumulatively added into the organ bath to produce vasodilation.

Fourth, the effect of linolenic acid on the vasodilation induced by cyclic guanosine monophosphate (cGMP) analog 8-bromoguanosine 3',5'-cyclic monophosphate sodium salt (bromo-cGMP), nonspecific vasodilator papaverine, and calcium channel blocker diltiazem in endothelium-denuded rat aortae was examined. Isolated endothelium-denuded rat aortae were pretreated with linolenic acid (5 \times 10^{-5} M) for 20 minutes. Then, phenylephrine (10^{-7} M) was added into the organ bath to produce a sustained and stable contraction in the presence or absence of linolenic acid. Bromo-cGMP (10^{-10} to 10^{-4} M), papaverine (10^{-7} to 3 \times 10^{-7} M), and diltiazem (10^{-8} to 10^{-7} M) were cumulatively added into the organ bath to produce vasodilation.

Fifth, as the contraction induced by the \alpha-2 adrenoceptor agonist dexmedetomidine is inhibited by endothelial NO, the effect of linolenic acid on the contraction induced by dexmedetomidine in endothelium-intact rat aortae was examined. The isolated endothelium-intact rat aortae were pretreated with linolenic acid (5 \times 10^{-5} M) for 20 minutes. Then, dexmedetomidine (10^{-6} to 10^{-7} M) was cumulatively added into the organ bath to produce a dexmedetomidine–contracted response curve in the endothelium-intact rat aortae with or without linolenic acid and endothelium-denuded rat aortae to confirm that dexmedetomidine-induced contraction is attenuated by endothelial NO. After dexmedetomidine (10^{-6} M) produced maximal contraction in endothelium-intact rat aortae with or without linolenic acid, the nitric oxide synthase (NOS) inhibitor N\textsuperscript{\wedge}\textsuperscript{\wedge}-nitro-L-arginine methyl ester (L-NAME, 10^{-4} M) was added to the organ bath to produce L-NAME-induced contraction. In addition, as bupivacaine-induced contraction is attenuated by endothelial NO release, the effect of linolenic acid on the bupivacaine-induced contraction in endothelium-intact and endothelium-denuded aortae was investigated.

The endothelium-intact rat aortae were pretreated with linolenic acid (5 \times 10^{-5} M) or L-NAME (10^{-4} M) alone for 20 minutes or L-NAME (10^{-4} M) for 20 minutes followed by linolenic acid (5 \times 10^{-5} M) for 20 minutes. In addition, the endothelium-denuded aortae were pretreated with linolenic acid (5 \times 10^{-5} M) for 20 minutes. Then, bupivacaine (10^{-6} to 3 \times 10^{-4} M) was cumulatively added into organ bath to produce bupivacaine concentration–response curves in endothelium-intact and endothelium-denuded rat aortae in the presence or absence of linolenic acid and L-NAME alone and combined treatment with L-NAME and linolenic acid.

Finally, the effect of extracellular calcium on the bupivacaine-induced contraction was examined. Isolated endothelium-denuded aortae were treated with calcium-free Krebs solution for 20 minutes. Bupivacaine (2 \times 10^{-5} M) was added into the organ bath to produce vasoconstriction in the presence or absence of calcium-free Krebs solution. Then, calcium (1.25 and 2.5 mM) and linolenic acid (5 \times 10^{-5} M) were added into the organ bath, showing bupivacaine-induced contraction with and without calcium-free Krebs solution, respectively. In addition, the effects of endothelial denudation and L-NAME on the bupivacaine concentration–response curves in isolated rat aortae were examined. The endothelium-intact aortae were pretreated with L-NAME (10^{-4} M) for 20 minutes. Then, bupivacaine (10^{-6} to 3 \times 10^{-4} M) was cumulatively added into the organ bath with endothelium-intact or endothelium-denuded aortae and L-NAME-pretreated endothelium-intact aortae to produce bupivacaine concentration–response curves.

**Cell Culture**

Human umbilical vein endothelial cells (EA.hy926 cells, American Type Culture Collection, Manassas, Virginia) were cultured in Endothelial Cell Medium (ScienCell Research Laboratories, Carlsbad, California) supplemented with 20% fetal bovine serum, 1% penicillin and streptomycin, and 1% endothelial cell growth supplement, as described previously. Cells were plated onto gelatin (Difco, Becton Dickinson, New Jersey)-coated 100-mm culture dishes and incubated at 37°C in a humidified atmosphere containing 5% CO\textsubscript{2} with media change every 2 days. Upon reaching confluence, the cells were dissociated with 0.025% trypsin–ethylenediaminetetraacetic acid solution and split at a 1:4 ratio. For our experiments, cells between passages 2 and 5 were seeded on to dishes (10^5 cells/100-mm dish) and cultured until they reached 70% confluence, followed by serum starvation overnight prior to drug treatment.

**Western Blot Analysis**

Western blot analysis was carried out as described previously. Briefly, cells were lysed in the PRO-PREP protein extraction solution to isolate the total cell extract by centrifugation at 16,000 \times g for 15 minutes at 4°C. The protein concentrations were measured using the Bradford method. The protein samples to be loaded in the gel were prepared by mixing equal volumes of protein lysates with 2× sodium dodecyl sulfate sample buffer (0.1 M Tris–HCl, 20% glycerol, 4% sodium dodecyl sulfate, and 0.01% bromophenol blue). A total of 25 μg protein per sample was separated by 8% or 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for 90 minutes at 110 V. The separated proteins were electrophoretically...
transferred to polyvinylidene difluoride membranes for 1 hour at 190 mA. Then, the membranes were blocked in Tris-buffered saline containing TWEEN 20 (TBST) with 5% (wt/vol) nonfat dried milk for 1 hour at room temperature and incubated overnight at 4°C with specific primary antibodies (anti-endothelial NOS [eNOS] and anti-phospho-eNOS: Cell Signaling Technology, Beverly, Massachusetts) diluted 1:1000 in TBST containing 5% (wt/vol) skim milk powder or 5% bovine serum albumin. After washing the membranes in TBST, bound antibodies were incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse immunoglobulin G diluted 1:5000 in TBST containing 5% (wt/vol) skim milk for 1 hour at room temperature. The membranes were washed in TBST, and the immunoreactive bands were detected by chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate; Thermo Scientific, Rockford, Illinois) using X-ray film (Super RX-N Fuji Medical X-ray Film, Japan) or ChemiDoc Touch Imaging System (Bio-Rad Laboratories Inc, Berkeley, California).

**Cyclic GMP Measurement**

Cyclic GMP measurement was performed as described previously.24 The descending thoracic aortic strips were immersed in organ bath with 10 mL Krebs solution for 60 minutes. Endothelium-denuded thoracic aortic strips from the same rat aorta were untreated with drugs and treated with sodium nitroprusside (10⁻⁷ M) alone for 1 minute and linolenic acid (5 × 10⁻⁵ M) for 30 minutes followed by sodium nitroprusside (10⁻⁷ M) for 1 minute. Endothelium-intact thoracic aortic strips from the same rat aorta were untreated with drugs and treated with bupivacaine (3 x 10⁻⁴ M) alone for 1 minute or linolenic acid (5 × 10⁻⁵ M) alone for 31 minutes, linolenic acid (5 × 10⁻⁵ M) for 30 minutes followed by bupivacaine (3 × 10⁻⁴ M) for 1 minute, and L-NAME (10⁻⁴ M) for 30 minutes followed by bupivacaine (3 x 10⁻⁴ M) for 1 minute. Endothelium-intact thoracic aortic strips from the same rat aorta were untreated with drugs or treated with acetylcholine (10⁻⁵ M) alone for 1 minute, linoleic acid (5 × 10⁻⁵ M) alone for 21 minutes, or linoleic acid (5 × 10⁻⁵ M) for 20 minutes followed by acetylcholine (10⁻⁵ M) for 1 minute. Then, aortic strips were frozen in liquid nitrogen, homogenized in 0.1 M HCl. The acidic supernatants were used, and the assays were measured by ELISA using the cGMP Complete Kit obtained from Abcam (Cambridge Science Park, Cambridge, England). Levels of cGMP in each strip were expressed as pmol/mL.

**Materials**

All the chemicals with the highest purity were obtained from commercially available companies. Linolenic and linoleic acid, phenylephrine, acetylcholine, calcium ionophore A23187, sodium nitroprusside, bromo-cGMP, papaverine, diltiazem, and L-NAME were obtained from Sigma-Aldrich (St Louis, Missouri). Linolenic acid was dissolved in ethanol (final concentration of organ bath: 0.1%). Dexametomidine and bupivacaine were obtained from Orion Pharma (Turku, Finland) and Reyon Pharmaceutical Company (Seoul, Korea), respectively. The calcium ionophore A23187 was dissolved in dimethyl sulfoxide. Unless stated, other drugs were dissolved in distilled water. All chemical concentrations are expressed as the final molar concentration.

**Statistical Analysis**

Data are shown as the mean ± standard deviation. Data are expressed as the percentage of maximal contraction induced by phenylephrine or isotonic 60 mM KCl. The effects of linolenic and linoleic acid, ethanol, GW1100, L-NAME, endothelial denudation and calcium-free Krebs solution, alone or combined, on vasodilation or vasoconstriction induced by acetylcholine, calcium ionophore A23187, sodium nitroprusside, bromo-cGMP, papaverine, diltiazem, dexametomidine, and bupivacaine were analyzed using 2-way repeated-measures analysis of variance (ANOVA), followed by Bonferroni multiple comparison test. The effect of linolenic acid or calcium on the bupivacaine-induced contraction in the Krebs solution or calcium-free Krebs solution was analyzed using repeated-measures ANOVA, followed by Bonferroni multiple comparison test. The effect of linolenic and linoleic acid on eNOS phosphorylation and cGMP levels induced by bupivacaine, acetylcholine, and sodium nitroprusside was analyzed using 1-way ANOVA, followed by Bonferroni multiple comparison test. A P value less than .05 was considered statistically significant.

**Results**

Linolenic acid (5 × 10⁻⁶ and 5 × 10⁻⁵ M) inhibited acetylcholine-induced relaxation (Figure 1A; P < .05 vs control at 10⁻⁷, 3 × 10⁻⁶, and 10⁻⁵ M) in endothelium-intact rat aortae in a concentration-dependent manner, whereas a higher concentration of linoleic acid (5 × 10⁻⁵ M) inhibited acetylcholine-induced relaxation (Figure 1B; P < .05 vs control at 3 × 10⁻⁷ to 10⁻⁵ M) in endothelium-intact rat aortae. Linolenic acid (5 × 10⁻⁵ M) inhibited calcium ionophore A23187-induced vasodilation (Figure 2A; P < .01 vs control at 3 × 10⁻⁸ to 3 × 10⁻⁷ M) in endothelium-intact rat aortae. Calcium ionophore A23187 (3 × 10⁻⁷ M) produced maximal vasodilation in the control group with endothelium-intact aorta, and the highest concentration of calcium ionophore A23187 (10⁻⁶ M) produced vasodilation in endothelium-intact aorta pretreated with linolenic acid (Figure 2A). In addition, linolenic acid (5 × 10⁻⁵ M) attenuated sodium nitroprusside-induced vasodilation in endothelium-denuded rat aortae (Figure 2B; P < .001 vs control at 3 × 10⁻⁹ to 3 × 10⁻⁸ M). The G-protein–coupled receptor 40 inhibitor GW1100 had no effect on acetylcholine-induced relaxation in endothelium-intact rat aortae treated with linoleic acid (5 × 10⁻⁵ M, Figure 3A). Ethanol (0.1%) had no effect on acetylcholine-induced relaxation in endothelium-intact rat
aortae (Figure 3B). However, linolenic acid \(5 \times 10^{-5} \text{ M}\) increased vasodilation induced by the cGMP analog bromocGMP in endothelium-denuded rat aortae (Figure 4A; \(P < .05\) vs control at \(10^{-4}\) M). In addition, linolenic acid \(5 \times 10^{-5} \text{ M}\) enhanced vasodilation induced by nonspecific vasodilator papaverine (Figure 4B; \(P < .001\) vs control at \(10^{-5}\) M) and calcium channel blocker diltiazem (Figure 4C; \(P < .001\) vs control at \(10^{-6}\) to \(10^{-4}\) M). Linolenic acid increased dexmedetomidine-induced contraction (Figure 5A and B; \(P < .01\) vs control at \(3 \times 10^{-7}\) and \(10^{-6}\) M) in endothelium-intact aortae. However, post-treatment with \(l\)-NAME did not significantly alter dexmedetomidine \(10^{-9} \text{ M}\)-induced contraction.
in endothelium-intact rat aortae pretreated with or without linolenic acid (Figure 5B). Linolenic acid (5 × 10⁻⁵ M) increased bupivacaine-induced contraction in endothelium-intact aortae (Figure 6A; P < .01 vs control at 3 × 10⁻⁵ to 3 × 10⁻⁴ M). However, linolenic acid attenuated bupivacaine-induced contraction in both endothelium-intact aortae with L-NAME and endothelium-denuded aortae (Figure 6B and C; P < .01 vs L-NAME alone or control at 10⁻⁵ and 3 × 10⁻⁵ M). In particular, L-NAME pretreatment or endothelial denudation abolished linolenic acid-mediated attenuation of a toxic
concentration of bupivacaine (3 × 10⁻⁴ M)-induced vasodila-
tion (Figure 6A-C). Calcium-free Krebs solution nearly abol-
ished bupivacaine (2 × 10⁻⁵ M)-induced contraction (Figure
7A; P < .001 vs bupivacaine in the Krebs solution). Subse-
quent addition of calcium chloride (1.25 and 2.5 mM)
increased bupivacaine (2 × 10⁻⁵ M)-induced contraction of
calcium-free Krebs solution in a concentration-dependent manner (Figure 7A; \( P < .001 \)). Linolenic acid (5 × 10^{-5} M) also inhibited bupivacaine (2 × 10^{-5} M)-induced contraction in Krebs solution (Figure 7A; \( P < .001 \)). Bupivacaine-induced contraction was attenuated in endothelium-intact rat aortae compared with endothelium-denuded rat aortae (Figure 7B; \( P < .001 \) at 10^{-5} to 3 × 10^{-4} M), whereas pretreatment with L-NAME enhanced bupivacaine-induced contraction in endothelium-intact rat aortae (Figure 7B; \( P < .001 \) at 10^{-5} to 3 × 10^{-4} M).

Linolenic acid (5 × 10^{-6} and 5 × 10^{-5} M) and linoleic acid (5 × 10^{-5} M) inhibited acetylcholine (10^{-5} M)-induced eNOS phosphorylation (at Ser1177) in human umbilical vein endothelial cells (Figure 8A; \( P < .001 \) vs acetylcholine alone). Bupivacaine (3 × 10^{-4} M) induced eNOS phosphorylation (at Ser1177) in human umbilical vein endothelial cells (Figure 8B; \( P < .01 \) vs control). However, linolenic acid (5 × 10^{-5} M) inhibited bupivacaine (3 × 10^{-4} M)-induced eNOS phosphorylation (Figure 8B; \( P < .001 \) vs bupivacaine alone).

Linolenic acid (5 × 10^{-5} M) decreased sodium nitroprusside (10^{-7} M)-induced increased cGMP formation (\( P < .001 \) vs sodium nitroprusside; Figure 9A) in endothelium-denuded aortic strips. Bupivacaine (3 × 10^{-4} M) decreased cGMP formation (Figure 9B; \( P < .001 \) vs control) in endothelium-intact aortic strips. Pretreatment with linolenic acid (5 × 10^{-5} M) or L-NAME (10^{-4} M) further reduced the bupivacaine (3 × 10^{-4} M)-induced decrease in cGMP formation in the endothelium-intact aortic strip (Figure 9B; \( P < .01 \) vs bupivacaine alone). In addition, acetylcholine (10^{-5} M) increased cGMP formation in endothelium-intact aortic strips (Figure 9C; \( P < .001 \) vs control). However, linoleic acid (5 × 10^{-5} M) inhibited acetylcholine-induced cGMP formation in isolated endothelium-intact aortic strips (Figure 9C; \( P < .001 \) vs acetylcholine alone).

**Discussion**

This study suggests that linolenic acid inhibits acetylcholine-induced NO-mediated relaxation in endothelium-intact rat aortae via the inhibition of site just upstream of cGMP formation. The major findings of this study are as follows: (1) Linolenic acid more potently inhibited acetylcholine-induced relaxation than linoleic acid; (2) linolenic acid inhibited vasodilation induced by calcium ionophore A23187 and it did not produce the calcium ionophore A23187 (10^{-6} M)-induced vasoconstriction observed in the control group; (3) linolenic acid decreased the vasodilation induced by sodium nitroprusside; (4) linolenic acid attenuated vasodilation induced by a toxic concentration of bupivacaine (3 × 10^{-4} M) in endothelium-intact rat aortae (Figure 6A), whereas L-NAME and endothelial denudation abolished linolenic acid-mediated attenuation of vasodilation induced by a toxic concentration of bupivacaine (Figure 6B and C); and (5) linolenic acid inhibited bupivacaine-induced eNOS phosphorylation and further reduced cGMP formation decreased by bupivacaine.
Nitric oxide is produced from L-arginine by NOS in the endothelium, which is activated by calmodulin in a calcium-dependent manner. Then, NO is transferred from the endothelium to vascular smooth muscle and then activates guanylate cyclase. Subsequently, activated guanylate cyclase leads to the formation of cGMP, which leads to vasodilation through cGMP-dependent protein kinase. The clinically relevant concentration associated with the partitioning effect of Intralipid used for the treatment of drug toxicity as a nonspecific antidote seems to be a 1% lipid emulsion. Linolenic acid contained in 1% Intralipid is approximately 2.8 × 10⁻³ M. Similar to a previous report, 5 × 10⁻⁶ and 5 × 10⁻⁵ M linolenic acid, which is approximately 1.78 × 10⁻³ to 1.78 × 10⁻² times lower than the clinically relevant concentration of linolenic acid, attenuated acetylcholine-induced relaxation (Figure 1A). In addition, ethanol, which is used for dissolution of linolenic acid, had no effect on acetylcholine-induced vasodilation (Figure 3B). However, a high concentration of linoleic acid (5 × 10⁻⁵ M) inhibited acetylcholine-induced relaxation (Figure 1B). This difference may be due to the number of double bonds (3 vs 2) and the position of the first double bond from CH₃ (n-3 vs n-6) in these polyunsaturated essential fatty acids. In agreement with these results from the tension study, linolenic acid and linoleic acid inhibited eNOS phosphorylation induced by acetylcholine (Figure 8A). Linolenic acid attenuated vasodilation induced by the calcium ionophore A23187 (Figure 2A), which increases endothelial calcium and subsequently activates endothelial NOS. In addition, linolenic acid inhibited NO donor sodium nitroprusside-induced vasodilation in endothelium-denuded rat aortae (Figure 2B). In agreement with these results of the tension study, linolenic acid inhibited sodium nitroprusside-induced increased cGMP formation (Figure 9A). In addition, linoleic acid decreased the cGMP production induced by acetylcholine (Figure 9C). However, linolenic acid increased cGMP analog bromo-cGMP-induced vasodilation (Figure 4A). Taken together, the evidence suggests that the
hemodynamic changes, including increased blood pressure and left ventricular systolic pressure, increased systemic vascular resistance, and decreased arterial compliance observed after administration of Intralipid in the previous in vivo studies, may be partially due to linoleic acid-mediated inhibition of NO-induced vasodilation observed in the current study.4-7 Free fatty acid receptors stimulated by fatty acids are involved in the physiologic response and energy metabolism.27 However, GW1100 had no effect on the linoleic acid-mediated inhibition of acetylcholine-induced relaxation (Figure 3A), suggesting that this response does not involve activation of G-protein-coupled receptor 40. As the apoptosis produced by a metabolite derived from linoleic acid is mediated by peroxisome proliferator-activated receptor-γ, further study regarding whether linoleic acid-mediated inhibition of acetylcholine-induced vasodilation is mediated by peroxisome proliferator-activated receptor-γ is needed.28 Linolenic acid increased dexmedetomidine-induced contraction in endothelium-intact rat aortae (Figure 5A), whereas post-treatment with l-NAME abolished the linolenic acid-mediated increase in dexmedetomidine (10⁻⁶ M)-induced contraction (Figure 5B), suggesting that linolenic acid seems to be an inhibitory effect on the dexmedetomidine-induced NO production pathway. Furthermore, linolenic acid (5 x 10⁻⁵ M) increased bupivacaine-induced contraction in endothelium-intact aortae (Figure 6A). However, linolenic acid attenuated bupivacaine-induced contraction in l-NAME-pretreated endothelium-intact and endothelium-denuded aortae (Figure 6B and C). Taken together (Figure 6A-C), our results suggest that linolenic acid-mediated augmentation of contraction induced by bupivacaine in endothelium-intact aortae is mediated by inhibition of endothelial NO release, which seems to be modulated via inhibitory effect of linolenic acid on bupivacaine-induced contraction in vascular smooth muscle (Figures 6C and 7A). In agreement with the isometric tension study, linolenic acid inhibited bupivacaine-induced eNOS phosphorylation (Figure 8B). Consistent with a previous study, a toxic concentration of bupivacaine (3 x 10⁻⁴ M) induced eNOS phosphorylation (Figure 8B). However, calcium-dependent vascular smooth muscle contraction activates calcium-dependent phosphodiesterase to reduce cGMP levels.29 Thus, although bupivacaine increased eNOS phosphorylation (Figure 8B), the bupivacaine-induced decrease in the cGMP level observed in the endothelium-intact aortic strip (Figure 9B) seems to be due to the antagonizing effect of calcium-dependent bupivacaine-induced smooth muscle contraction (Figure 7A) on the endothelial NO-induced cGMP production induced by bupivacaine in the isolated endothelium-intact aortic strip. Linolenic acid and l-NAME further decreased bupivacaine-induced cGMP formation (Figure 9B), which contributes to an increased bupivacaine-induced contraction in endothelium-intact aortae treated with linolenic acid or l-NAME (Figures 6A and 7B).

Linolenic acid increased the vasodilation induced by non-specific vasodilator papaverine, which produces vasodilation via both inhibition of phosphodiesterase to produce increased amounts of cGMP and cyclic adenosine monophosphate and inhibition of calcium influx.30,31 In addition, linolenic acid enhanced vasodilation induced by diltiazem, which produces vasodilation via inhibition of calcium influx.32 As polyunsaturated fatty acid inhibits voltage-dependent L-type calcium current, this enhancement of vasodilation induced by papaverine (Figure 4B) and diltiazem (Figure 4C) may be associated with...
linolenic acid’s inhibition of calcium channels. Similar to these results, the highest concentration (10⁻⁶ M) of calcium ionophore A23187 produced vasoconstriction in the control group, whereas it produced maximal vasodilation in linolenic acid group, which may be due to the inhibitory effect of linolenic acid on the calcium influx into vascular smooth muscle induced by calcium ionophore A23187 (10⁻⁶ M). Moreover, similar to previous reports involving aminoamide local anesthetics, the calcium-free state nearly abolished bupivacaine-induced contraction and the subsequent addition of calcium increased bupivacaine-induced contraction (Figure 7A), suggesting that linolenic acid may inhibit calcium influx from the extracellular space. Thus, further study regarding the effect of linolenic acid on the intracellular calcium level is needed. In contrast to the inhibitory effect of linolenic acid on NO-induced relaxation, linolenic acid-induced enhancing effects of vasodilation caused by papaverine and bromocriptine appear to be associated with the site below cGMP formation. Therefore, this linolenic acid-mediated inhibition of NO-induced vasodilation may be specific.

In agreement with previous reports using aminoamide local anesthetics, the vasodilation induced by a toxic concentration (3 × 10⁻⁴ M) of bupivacaine is mediated by NO (Figure 7B). In addition, a lipid emulsion containing linolenic acid reverses vasodilation induced by a toxic concentration of levobupivacaine in endothelium-intact aortae and reduces levobupivacaine-induced eNOS phosphorylation in human umbilical vein endothelial cells and rat aortic endothelium. Taken together, the evidence suggests that linolenic acid-induced inhibition of vasodilation caused by NO observed in the current study appears to partially contribute to lipid emulsion-mediated inhibition of severe vasodilation (vascular collapse) caused by NO release induced by toxic concentrations of local anesthetics. In addition, as linolenic acid increased dexamethasone-induced contraction in endothelium-intact aortae, a patient concurrently taking Intralipid and dexamethasone for parenteral nutrition and sedation, respectively, in the intensive care unit may show slightly increased blood pressure compared with a patient taking only dexamethasone. However, this study has some limitations. First, the aorta was used for isometric tension measurement in the current study, whereas human umbilical vein endothelial cells were used to investigate eNOS phosphorylation. Second, fatty acids in the lipid emulsion (Intralipid) used for the treatment of drug toxicity are triglyceride forms, whereas free fatty acids were used in the current study. Third, Intralipid contains several long-chain fatty acids, but we examined the effect of essential fatty acids on acetylcholine-induced relaxation.

In conclusion, linolenic acid attenuated acetylcholine-induced NO-mediated relaxation via the inhibition of NO-induced guanylate cyclase activation after NO formation. In addition, linolenic acid seems to contribute to the attenuation of severe vasodilation induced by a toxic concentration (3 × 10⁻⁴ M) of bupivacaine via the inhibition of the endothelial NO–cGMP pathway.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1D1A1B07043914 and NRF-2016R1D1A1B03930451).

ORCID iD
Ju-Tae Sohn https://orcid.org/0000-0003-0102-5800

References
1. Ok SH, Hong JM, Lee SH, Sohn JT. Lipid emulsion for treating local anesthetic systemic toxicity. Int J Med Sci. 2018;15(7):713-722.
2. Weinberg GL. Lipid emulsion infusion: resuscitation for local anesthetic and other drug overdose. Anesthesiology. 2012;117(1):180-187.
3. Ok SH, Lee SH, Yu J, et al. Lipid emulsion attenuates acetylcholine-induced relaxation in isolated rat aorta. Biomed Res Int. 2015;2015:871545. doi:10.1155/2015/871545.
4. Shin IW, Hah YS, Kim C, et al. Systemic blockage of nitric oxide synthase by l-NAME increases left ventricular systolic pressure, which is not augmented further by Intralipid®. Int J Biol Sci. 2014;10(4):367-376.
5. Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM. Hemodynamic effects of lipids in humans. Am J Physiol Regul Integr Comp Physiol. 2001;280(6):R1674-R1679.
6. Umpierrez GE, Smiley D, Robalino G, et al. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(2):609-614.
7. Van de Velde M, Wouters PF, Rolf N, Van Aken H, Vandermeersch E. Comparative hemodynamic effects of three different parenterally administered lipid emulsions in conscious dogs. Crit Care Med. 1998;26(1):132-137.
8. Fettplace MR, Ripper R, Lis K, et al. Rapid cardiotoxic effects of lipid emulsion infusion. Crit Care Med. 2013;41(8):e156-e162.
9. Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr. 2007;85(5):1171-1184.
10. Edirisinghe I, McCormick Hallam K, Kappagoda CT. Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta. Clin Sci (Lond). 2006;111(2):145-151.
11. Baik JS, Sohn JT, Ok SH, et al. Levobupivacaine-induced contraction of isolated rat aorta is calcium dependent. Can J Physiol Pharmacol. 2011;89(7):476-476.
12. Sung HJ, Choi MJ, Ok SH, et al. Mepivacaine-induced contraction is attenuated by endothelial nitric oxide release in isolated rat aorta. Can J Physiol Pharmacol. 2012;90(7):863-872.
13. Ok SH, Han JY, Sung HJ, et al. Ropivacaine-induced contraction is attenuated by both endothelial nitric oxide and voltage-dependent calcium channel inhibitors. Anesth Analg. 2008;106(7):2109-2115.
dependent potassium channels in isolated rat aortae. *Biomed Res Int.* 2013;2013:565271. doi:10.1155/2013/565271.

14. Ok SH, Sohn JT, Baik JS, et al. Lipid emulsion reverses levobupivacaine-induced responses in isolated rat aortic vessels. *Anesthesiology* 2011;114(2):293-301.

15. Ok SH, Park CS, Kim HJ, et al. Effect of two lipid emulsions on reversing high-dose levobupivacaine-induced reduced vasoconstriction in the rat aortas. *Cardiovasc Toxicol.* 2013;13(4):370-380.

16. Kaplan HM, Kuyucu Y, Polat S, et al. Molecular basis of vascular damage caused by cigarette smoke exposure and a new approach to the treatment: alpha-linolenic acid. *Biomed Pharmacother.* 2018;102:458-463.

17. Das UN. Biological significance of essential fatty acids. *J Assoc Physicians India.* 2006;54:309-319.

18. Lee SH, Park CS, Ok SH, et al. Bupivacaine-induced contraction is attenuated by endothelial nitric oxide release modulated by activation of both stimulatory and inhibitory phosphorylation (Ser1177 and Thr495) of endothelial nitric oxide synthase. *Eur J Pharmacol.* 2019;853:121-128.

19. Lee SH, Kim JY, Kim S, Sohn JT. The effect of sugammadex on the vascular tone of isolated rat aorta. *Korean J Anesthesiol.* 2018;71(3):242-243.

20. Kim SO, Toda H, Nakamura K, et al. Thiopental attenuates relaxation and cyclic GMP production in vascular smooth muscle of endotoxin-treated rat aorta, independent of nitric oxide production. *Br J Anaesth.* 1998;81(4):601-602.

21. Takahashi K, Fukushima K, Onishi Y, et al. Different effects of G-protein-coupled receptor 120 (GPR120) and GPR40 on cell motile activity of highly migratory osteosarcoma cells. *Biochem Biophys Res Commun.* 2017;484(3):675-680.

22. Kim HJ, Sohn JT, Jeong YS, et al. Direct effect of dexametomidine on rat isolated aorta involves endothelial nitric oxide synthesis and activation of the lipooxygenase pathway. *Clin Exp Pharmacol Physiol.* 2009;36(4):406-412.

23. Byon HJ, Ok SH, Lee SH, et al. Dexametomidine inhibits phenylephrine-induced contractions via alpha-1 adrenoceptor blockade and nitric oxide release in isolated rat aortae. *Int J Med Sci.* 2017;14(2):143-149.

24. Minamoto Y, Nakamura K, Toda H, et al. Suppression of acetylcholine-induced relaxation by local anesthetics and vascular NO-cyclic GMP system. *Acta Anaesthesiol Scand.* 1997;41(8):1054-1060.

25. Sohn JT, Kim HJ, Cho HC, Shin IW, Lee HK, Chung YK. Effect of etomidate on endothelium-dependent relaxation induced by acetylcholine in rat aorta. *Anaesth Intensive Care.* 2004;32(4):476-481.

26. Fettiplace MR, Akpa BS, Rubinstein I, Weinberg G. Confusion about infusion: rational volume limits for intravenous lipid emulsion during treatment of oral overdoses. *Ann Emerg Med.* 2015;66(2):185-188.

27. Hara T, Kashiwara D, Ichimura A, Kimura I, Tsujimoto G, Hiraseawa A. Role of free fatty acid receptors in the regulation of energy metabolism. *Biochim Biophys Acta.* 2014;1841(9):1292-1300.

28. Cabral M, Martin-Venegas R, Moreno JJ. Differential cell growth/apoptosis behavior of 13-hydroxyoctadecadienoic acid enantiomers in a colorectal cancer cell line. *Am J Physiol Gastrointest Liver Physiol.* 2014;307(6):G664-G671.

29. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. *Circ Res.* 2003;93(4):280-291.

30. Abusnina A, Lugnier C. Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families. *Cell Signal.* 2017;39:55-65.

31. Aoki H, Nishimura J, Kobayashi S, Kanaide H. Relationship between cytosolic calcium concentration and force in the papaverine-induced relaxation of medial strips of pig coronary artery. *Br J Pharmacol.* 1994;111(2):489-496.

32. Elliott WJ, Ram CV. Calcium channel blockers. *J Clin Hypertens (Greenwich).* 2011;13(9):687-689.

33. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca$^{2+}$ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. *Proc Natl Acad Sci U S A.* 1997;94(8):4182-4187.

34. Tokinaga Y, Ogawa K, Yu J, Kuriyama T, Minonishi T, Hatano Y. Mechanism of the ropivacaine-induced increase in intracellular Ca$^{2+}$ concentration in rat aortic smooth muscle. *Acta Anaesthesiol Scand.* 2007;51(9):1155-1160.

35. Regenthal R, Krueger M, Koeppe C, Preiss R. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. *J Clin Monit Comput.* 1999;15(7-8):529-544.